Eli Lilly has announced a deal valued at up to $2.3 billion to acquire Ajax Therapeutics and its lead Type II JAK2 inhibitor, AJ1‑11095. The compound entered phase 1 testing in 2024 for myelofibrosis patients who had already been treated with Type I JAK2 inhibitors such as Jakavi (Novartis/Incyte) and Inrebic (Bristol Myers Squibb). Lilly, a founding strategic investor in Ajax’s $95 million Series C round the same year, expects clinical proof‑of‑concept data in 2026 and aims to move the candidate quickly into registrational development. Beyond the headline figure, the company has not disclosed additional financial terms.
This acquisition extends Lilly’s fast‑paced M&A streak and adds another high‑potential program to its hematology portfolio. By targeting the Type II conformation of JAK2, AJ1‑11095 is designed to overcome resistance and improve disease control, limitations that have blunted first‑generation agents. Lilly already markets Olumiant for autoimmune conditions, giving it a well‑established understanding of JAK pharmacology and the safety issues regulators watch closely. Paying what amounts to near‑late‑stage multiples for a phase 1 compound signals clear conviction that this mechanism could reset expectations in myeloproliferative neoplasms. Some on the Street think that’s bold; it probably is.
Investors now need to track how quickly phase 1 results emerge and whether safety stands apart from Type I inhibitors, which carry class warnings. Lilly’s projection of first data by year‑end 2026 will set the pace. If results show meaningful differentiation, competitors including BMS and Incyte will be forced to recalibrate clinical strategy. For payers, a durable JAK2 therapy could alter sequencing logic and pricing power across the category. The broader pattern is hard to miss, high‑velocity, high‑value oncology deals are crowding the early pipeline stage, and large firms seem more willing to buy optionality before proof fully ripens. The data cycle may shift; nobody really knows yet. For deeper analysis of oncology deal flow and pricing dynamics, see RxInfo.ai.
